de Soyza N, Terry L, Murphy M L, Thompson C H, Doherty J E, Sakhaii M, Dinh H
Am Heart J. 1984 Aug;108(2):285-9. doi: 10.1016/0002-8703(84)90613-6.
Thirty patients with clinically significant ventricular ectopy were treated with propafenone, a new potent antiarrhythmic agent with membrane stabilizing action. Patients had a minimum mean of greater than 30 ventricular premature beats per hour documented by continuous 48-hour ambulatory ECG recording. Twenty-five patients qualified as responders, defined as greater than 85% reduction of ventricular ectopy compared to baseline, and completed a double-blind placebo-crossover phase. Significant reduction in single ventricular ectopy per hour, paired ventricular ectopy per hour, and ventricular tachycardia beats per hour were observed. Almost total abolition of ventricular tachycardia and paired ventricular ectopy was achieved. Side effects were minimal and well tolerated. A significant prolongation of the PR interval occurred. QRS prolongation and prolongation of the corrected QT interval was observed in some patients, with new left bundle branch block developing in two patients. Long-term efficacy and safety studies will be necessary to determine the ultimate role of this new agent in the selection of antiarrhythmic therapy, but these initial results are encouraging.
30例有临床意义的室性早搏患者接受了普罗帕酮治疗，普罗帕酮是一种新型强效抗心律失常药物，具有膜稳定作用。通过连续48小时动态心电图记录，患者每小时室性早搏的平均次数最少超过30次。25例患者被判定为有反应者，定义为与基线相比室性早搏减少超过85%，并完成了双盲安慰剂交叉阶段。观察到每小时单形性室性早搏、成对室性早搏和室性心动过速次数显著减少。几乎完全消除了室性心动过速和成对室性早搏。副作用轻微且耐受性良好。PR间期有显著延长。部分患者观察到QRS增宽和校正QT间期延长，2例患者出现新的左束支传导阻滞。需要进行长期疗效和安全性研究以确定这种新药在抗心律失常治疗选择中的最终作用，但这些初步结果令人鼓舞。
